JP6757601B2 - Physiological absorbent articles - Google Patents

Description

The present invention relates to a sanitary absorbent article that can be used during menstruation.

Menstrual blood has a higher viscosity than urine and tends to remain on the surface of sanitary napkins. Therefore, the wearer tends to feel dissatisfaction such as leakage of menstrual blood or getting wet while using the sanitary napkin. In addition, the menstrual blood remaining on the surface adheres to the wearer's skin, which makes it easy to feel itching and stuffiness, which may lead to skin troubles. Such skin troubles are more likely to occur as the diffusion area of menstrual blood increases during the use of sanitary napkins. It is considered that the expansion of the diffusion area of menstrual blood is likely to occur due to the slow absorption of the absorber into the absorbent polymer and the return of the liquid.

Further, there is known a technique of applying an agent that acts on blood itself to change the state of blood to an absorbent article to improve various performances of the absorbent article. Patent Document 1 discloses a napkin containing a partially hydrated dicarboxylic acid anhydride copolymer or a polycation as a blood gelling agent. Patent Document 2 proposes a personal care absorbent article containing a triblock polymer containing polypropylene oxide and polyethylene oxide or a polycation as a fluid treatment material.

Further, as a technique different from these, Patent Document 3 describes a first portion exposed on the front surface of the absorber, a second portion exposed on the back surface of the absorber, a first portion, and a second portion. An absorbent article comprising an absorber containing a thermoplastic resin fiber having a connecting portion connecting the portions of the above has been proposed.

Japanese Unexamined Patent Publication No. 57-153648 Special Table 2002-528232 Japanese Unexamined Patent Publication No. 2015-16296

Patent Document 1 and Patent Document 2 do not describe anything about the configuration in which a second sheet made of non-woven fabric is arranged between the surface sheet and the absorber, and the agent and the second sheet that naturally change the blood state are used. No description or suggestion has been made regarding the placement relationship.

Patent Document 3 does not describe anything about the use of a hemagglutinant, nor does it describe a configuration in which a second sheet made of non-woven fabric is arranged between the surface sheet and the absorber. Therefore, Patent Document 3 does not naturally describe or suggest the arrangement relationship between the second sheet and the hemagglutination agent.

Therefore, an object of the present invention is to provide a physiologically absorbent article capable of eliminating the above-mentioned drawbacks of the prior art.

The present invention comprises an absorber containing a highly absorbent polymer, a front sheet and a back sheet sandwiching the absorber, and a second sheet composed of a non-woven fabric arranged between the front sheet and the absorber. The sanitary absorbable article comprises a blood cell flocculant, the absorber contains synthetic fibers and cellulosic fibers, and the synthetic fibers are said to absorb. It has fibers containing a portion oriented in the thickness direction inside the body, and the blood cell flocculant is a non-skin facing surface side in contact with the absorber in the second sheet, or the second in the absorber. It is intended to provide a sanitary absorbent article existing on the side facing the skin in contact with the sheet.

According to the sanitary absorbable article of the present invention, the absorption rate of absorbing blood is high, liquid return is unlikely to occur, and menstrual blood can be absorbed in spots.

FIG. 1 is a plan view of a sanitary napkin, which is a preferred embodiment of a sanitary absorbent article for menstrual blood absorption of the present invention. FIG. 2 is a cross-sectional view schematically showing a cross section taken along line II-II of FIG. FIG. 3 is an enlarged cross-sectional view of a second sheet and an absorber included in the sanitary napkin shown in FIG. FIG. 4 is an enlarged schematic cross-sectional view of a main part of one absorbent sheet and a second sheet constituting the absorber shown in FIG. FIG. 5 is a perspective view of a surface sheet included in the sanitary napkin shown in FIG.

Hereinafter, the sanitary absorbent article of the present invention will be described with reference to the drawings based on the sanitary napkin 1 (hereinafter, also referred to as “napkin 1”) which is a preferred embodiment thereof. The napkin 1 is composed of an absorber 4 containing a highly absorbent polymer 41, a front surface sheet 2 and a back surface sheet 3 sandwiching the absorber 4, and a non-woven fabric arranged between the front surface sheet 2 and the absorber 4. It is provided with a second sheet 5 that has been made. Further, the napkin 1 includes a hemagglutination agent 8. The absorber 4 contains synthetic fibers 46 and cellulosic fibers 47 in addition to the highly absorbent polymer 41. FIG. 1 shows a plan view of a napkin 1, which is a preferred embodiment of the sanitary napkin article of the present invention, and FIG. 2 shows a cross-sectional view of the napkin 1. The sanitary absorbable article of the present invention is preferable for menstrual blood absorption.

In the present embodiment, the absorber 4 of the napkin 1 is formed of an absorbent sheet as shown in FIG. 2, and specifically, the absorbent sheet has a structure in which a plurality of layers are overlapped in the thickness direction Z. There is. In the napkin 1, the hemagglutination agent 8 is arranged on the second sheet 5 and the absorber 4 formed from the absorbent sheet (see FIG. 3). That is, in the napkin 1 of the present embodiment, the absorber 4 contains the highly absorbent polymer 41, the synthetic fiber 46, the cellulosic fiber 47, and the hemagglutination agent 8 (see FIG. 4). In the present embodiment, the napkin 1 is interposed between the liquid-permeable front surface sheet 2 that forms the skin facing surface, the back surface sheet 3 that forms the non-skin facing surface, and both sheets 2 and 3, and provides the absorber 4. It has an absorbent body 10 to be provided.

As shown in FIG. 1, the absorbent body 10 of the napkin 1 has an excretion portion facing portion B that is arranged to face the wearer's excretion portion (vaginal opening or the like) at the time of wearing, and the wearer rather than the excretion portion facing portion B. It has an anterior portion A arranged closer to the ventral side (front side) and a rear portion C arranged closer to the back side (rear side) of the wearer than the excretion portion facing portion B. The napkin 1 and the absorbent body 10 have a vertical direction X corresponding to the front-back direction of the wearer, a horizontal direction Y orthogonal to the vertical direction X, and a thickness direction Z. That is, the absorbent main body 10 is classified in the vertical direction X in the order of the front portion A, the excretion portion facing portion B, and the rear portion C.

Further, in the present specification, the skin-facing surface is the surface of the napkin 1 or its constituent members (for example, the surface sheet 2) that is directed toward the wearer's skin when the napkin 1 is worn, and the non-skin-facing surface is the napkin. This is a surface of 1 or its constituent members that faces the side opposite to the skin side (clothing side) when the napkin 1 is worn. Further, the vertical direction X corresponds to the longitudinal direction of the napkin 1 and the absorbent main body 10, and the horizontal direction Y corresponds to the width direction (direction orthogonal to the longitudinal direction) of the napkin 1 and the absorbent main body 10.

In the present embodiment, as shown in FIGS. 1 and 2, in addition to the absorbent main body 10, the napkin 1 is further laterally oriented from both side portions along the vertical direction X of the excretory portion facing portion B in the absorbent main body 10. It has a pair of wing portions 10W and 10W extending outward of Y.

In the sanitary absorbent article of the present invention, when the excretion portion facing portion B has a wing portion 10W like the napkin 1 of the present embodiment, the vertical direction (physiological absorbability) of the sanitary absorbent article A region having a wing portion 10W in the longitudinal direction of the article (X direction in the drawing) (a region sandwiched between the root of one wing portion 10W along the vertical direction X and the root of the other wing portion 10W along the vertical direction X). ) Means. The excretion part facing portion B in the sanitary absorbent article having no wing portion is formed when the sanitary absorbent article is folded into a tri-fold individual packaging form, and the sanitary absorbent article is laterally (physiologically used). Regarding the two folding curves (not shown) that cross the width direction of the absorbent article and the Y direction in the figure, the first folding curve and the second folding curve (not shown) are counted from the front end of the vertical direction X of the sanitary absorbent article. It means the area surrounded by the fold curve.

In the napkin 1 of the present embodiment, as shown in FIG. 1, the surface sheet 2 covers the entire surface of the absorber 4 facing the skin, and is outside the lateral direction Y from both side edges of the absorber 4 along the vertical direction X. It extends to the direction. On the other hand, the back surface sheet 3 covers the entire non-skin facing surface of the absorber 4, and further extends outward from both side edges along the vertical direction X of the absorber 4 in the horizontal direction Y, and the side sheet 7 described later. Together with this, the side flap portion 10S is formed. The front surface sheet 2 and the back surface sheet 3 are bonded to each other by known bonding means such as an adhesive, a heat seal, and an ultrasonic seal at the extending portions of the absorber 4 from both end edges in the vertical direction X. The front surface sheet 2 and the back surface sheet 3 and the absorber 4 may be bonded by an adhesive.

In the napkin 1, as shown in FIGS. 1 and 2, the side sheets 7 are arranged on both sides of the absorbent main body 10 on the skin-facing surface (skin-facing surface of the surface sheet 2) along the vertical direction X. Preferably, the side sheets 7 are arranged over the entire length of the absorbent body 10 in the vertical direction X so as to overlap the left and right side portions of the absorber 4 along the vertical direction X in a plan view.

In the napkin 1, as shown in FIG. 1, the pair of side sheets 7 and 7 have a linear first joint line 61 located at the excretion portion facing portion B and a vertical X of the first joint line 61, respectively. It is joined to the surface sheet 2 by a linear second joining line 62 located in front of and behind (front portion A and rear portion C). In the napkin 1, the first joint line 61 has a curved shape that is convex outward in the lateral direction Y in the plan view, and the second joint line 62 extends so as to alternately intersect in the vertical direction in the plan view. It is linear (zigzag linear). In this way, when the side sheet 7 is joined to the surface sheet 2 by the first joining line 61 and the second joining line 62 and fixed to the skin-facing surface of the absorbent main body 10, as shown in FIG. A space portion P defined by the side sheet 7 and the surface sheet 2 is formed inward in the lateral direction Y with respect to the first joint line 61 and the second joint line 62. Since this space P is open toward the center of the absorbent body 10 in the lateral direction Y, body fluid such as menstrual blood flowing outward from the center of the lateral Y is accommodated in the space P. As a result, leakage of body fluid can be effectively prevented. An elastic member in an extended state in the vertical direction X may be arranged at each free end of the pair of side sheets 7 and 7, and a pair of leak-proof cuffs along the vertical direction X may be arranged. The leak-proof cuff has an upright property and can prevent lateral leakage of menstrual blood arranged on the surface facing the skin.

In the napkin 1, as shown in FIG. 1, the side flap portion 10S projects largely outward in the lateral direction Y at the excretion portion facing portion B, whereby the left and right sides along the vertical direction X of the absorbent body 10 A pair of wing portions 10W and 10W are extended on both sides.

The wing portion 10W is used by being folded back toward the non-skin facing surface side of the crotch portion of clothing such as shorts. In the napkin 1, as shown in FIG. 1, the wing portion 10W has a substantially trapezoidal shape in which the lower base (the side longer than the upper base) is located on the side portion side along the vertical direction X of the absorbent body 10 in a plan view. It has a shape. On the non-skin facing surface of the wing portion 10W, a wing portion adhesive portion (not shown) for fixing the wing portion 10W (napkin 1) to clothing (not shown) such as shorts is formed, and this wing portion is formed. The adhesive portion allows the wing portion 10W folded back to the non-skin facing surface (outer surface) side of the crotch portion of the clothing to be adhesively fixed to the crotch portion during use. Further, on the non-skin facing surface of the absorbent main body 10, a main body adhesive portion (not shown) for fixing the absorbent main body 10 to clothes such as shorts is formed.

In the napkin 1, as shown in FIG. 2, a second sheet 5 made of a non-woven fabric is arranged between the surface sheet 2 and the absorber 4. In the napkin 1, the second sheet 5 covers substantially the entire area of the absorber 4 facing the skin, as shown in FIGS. 1 to 3. The second sheet 5 is a sheet that is separate from the surface sheet 2 and the absorber 4 and is also called a sub-layer sheet in the art. The second sheet 5 is a sheet that plays a role of improving the permeability of the liquid from the surface sheet 2 to the absorber 4 and reducing the liquid return of the liquid absorbed by the absorber 4 to the surface sheet 2. .. In the napkin 1, at least the second sheet 5 contains the hemagglutination agent 8.

FIG. 3 shows an enlarged cross-sectional view of the absorber 4 in the cross-sectional view shown in FIG. Further, FIG. 4 shows an enlarged cross-sectional view of a main part of one absorbent sheet constituting the absorber 4 shown in FIG. In the napkin 1, as shown in FIG. 4, one absorbent sheet contains a highly absorbent polymer 41 dispersed and arranged three-dimensionally, a synthetic fiber 46, a cellulosic fiber 47, and a hemagglutin 8. Have. The absorbent sheet is a polymer in which the mass ratio of the highly absorbent polymer 41 to the total amount of the mass of the fiber containing the synthetic fiber 46 and the cellulosic fiber 47 and the mass of the highly absorbent polymer 41 is relatively high in a cross-sectional view. It has a rich region PT and a fiber-rich region FT that is relatively lower than the polymer-rich region PT. In the napkin 1, the polymer-rich region PT and the fiber-rich region FT are divided in the thickness direction Z of the absorber 4 made of an absorbent sheet. The absorbent sheet contains fibers containing synthetic fibers 46 and cellulosic fibers 47, and has an integral structure in which the highly absorbent polymer 41 and the blood cell flocculant 8 are contained inside the absorber 4. As the absorbent sheet, the adhesive force generated in the highly absorbent polymer 41 in a wet state and the fibers containing the synthetic fiber 46 and the cellulosic fiber 47 via a binder such as an adhesive or an adhesive fiber added separately can be used. A sheet-like material obtained by bonding the highly absorbent polymer 41 with the fibers containing the synthetic fiber 46 and the cellulosic fiber 47 can be preferably used. The absorbent sheet is an absorbent body molded into a sheet shape, and is generally distinguished from an absorbent body having a fiber-stacked structure in which an absorbent material is stacked. Typical examples of the absorbent sheet include those described in Japanese Patent No. 2963647 and those described in Japanese Patent No. 2955223.

As the highly absorbent polymer 41 contained in the absorber 4, a particulate polymer is generally used, but a fibrous polymer may also be used. When a highly absorbent polymer in the form of particles is used, the shape may be spherical, lumpy, bale-shaped or amorphous. As the highly absorbent polymer, a polymer or copolymer of acrylic acid or an alkali metal salt of acrylic acid can generally be used. Examples thereof include polyacrylic acid and salts thereof, and polymethacrylic acid and salts thereof. As the polyacrylic acid salt and the polymethacrylic acid salt, a sodium salt can be preferably used. In addition, acrylic acid or methacrylic acid, maleic acid, itaconic acid, acrylamide, 2-acrylamide-2-methylpropanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2-hydroxyethyl (meth) acrylate, styrenesulfonic acid, etc. A copolymer obtained by copolymerizing the above comonomers without deteriorating the performance of the highly absorbent polymer can also be used.

The fibers included in the absorber 4 may include synthetic fibers 46 and cellulosic fibers 47, but are preferably formed only of synthetic fibers 46 and cellulosic fibers 47, and the napkin 1 of the present embodiment has , The fibers constituting the absorbent sheet of the absorber 4 are formed only of synthetic fibers 46 and cellulosic fibers 47. The ratio (content) of the synthetic fiber 46 to the absorber 4 is preferably 30% by mass or more, and more preferably 40% by mass or more, from the viewpoint of spot absorption of menstrual blood by the absorber 4. It is preferable, and it is preferably 80% by mass or less, more preferably 60% by mass or less, and specifically, 30% by mass or more and 80% by mass or less, and 40% by mass or more and 60% by mass. % Or less is more preferable. From the same viewpoint, the ratio (content) of the cellulosic fiber 47 in the absorber 4 is preferably 20% by mass or more, more preferably 40% by mass or more, and 70% by mass or less. It is more preferably 60% by mass or less, more preferably 20% by mass or more and 70% by mass or less, and further preferably 40% by mass or more and 60% by mass or less.

The synthetic fiber 46 is preferably a thermoplastic fiber, for example. The thermoplastic fiber was formed by using a single fiber formed by using a single synthetic resin such as polyethylene, polypropylene, polyester or polyurethane, or by using a synthetic resin such as a composite of two or more of these. Examples include composite fibers. Examples of the composite fiber include core-sheath type fiber, side-by-side type fiber, split fiber and the like. The fineness of the thermoplastic fiber (synthetic fiber 46) is preferably 0.5 dtex or more and 10 dtex or less, and more preferably 1.5 dtex or more and 5 dtex or less. The fiber length of the thermoplastic fiber (synthetic fiber 46) is preferably 6 mm or more and 70 mm or less, and more preferably 15 mm or more and 40 mm or less. The fiber length means the fiber length in the natural state.

Examples of the cellulose-based fiber 47 include crosslinked cellulose fibers (pulp fibers) in which intramolecular or intermolecular crosslinks of cellulose are crosslinked with an appropriate crosslinking agent, or regenerated cellulose fibers such as rayon fibers having improved crystallinity of cellulose. Can be mentioned. The fiber length of the cellulosic fiber 47 is preferably 3 mm or more and 70 mm or less, and more preferably 10 mm or more and 40 mm or less. The fiber length means the natural length. The fiber length means the fiber length in the natural state.

The hemagglutination agent 8 included in the napkin 1 acts to aggregate red blood cells in the blood so that the aggregates in which the red blood cells have aggregated and the plasma component are separated. A preferred hemagglutinant has the following properties. When 1000 ppm of the measurement sample agent is added to the simulated blood, when at least two or more erythrocytes aggregate to form an agglutinating mass while the blood fluidity is maintained, this measurement sample agent is used as a hemagglutination agent. And. Here, "the state in which the fluidity of blood is maintained" means that 10 g of pseudo blood to which 1000 ppm of the measurement sample agent is added is added to a screw tube bottle (Maruem product number "Screw tube No. 4", inner diameter 14.5 mm). , Body diameter 27 mm, total length 55 mm), and when the screw tube bottle containing the pseudo blood is inverted 180 degrees, it means a state in which 60% or more of the pseudo menstrual blood flows down within 20 seconds. Pseudoblood has a viscosity of 8 mPa · s measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 23 ° C., 60 seconds). The blood cell / plasma ratio of defibered horse blood (manufactured by Japan Biotest Research Institute Co., Ltd.) was prepared. Further, it is determined as follows whether or not "two or more erythrocytes aggregate to form an agglutinating mass". That is, the simulated blood to which 1000 ppm of the measurement sample agent was added was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring device (HORIBA model number: LA-950V2, measurement condition: flow type cell). The average median diameter of the volume particle size measured at a temperature of 25 ° C. by the laser diffraction / scattering method using measurement, circulation speed 1, and no ultrasonic waves corresponds to the size of agglomerates in which two or more red blood cells have aggregated. When it is 10 μm or more, it is determined that “two or more erythrocytes aggregate to form an agglomerate”.

The hemagglutination agent 8 included in the napkin 1 contains a cationic polymer. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride starch. The blood cell flocculant 8 may also contain, as a cationic polymer, a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate. In the present invention, the "quaternary ammonium salt" includes a compound having a positive monovalent charge at the position of the nitrogen atom or a compound that generates a positive monovalent charge at the position of the nitrogen atom by neutralization. Specific examples thereof include a salt of a quaternary ammonium cation, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution. The "quaternary ammonium moiety" described below is also used with the same meaning, and is a site that is positively charged in water. Further, in the present invention, the "copolymer" is a polymer obtained by copolymerizing two or more kinds of polymerizable monomers, and is a binary copolymer and a ternary or more copolymer. Includes both things. In the present invention, the "polycondensate" is a polycondensate obtained by polymerizing a condensate composed of two or more kinds of monomers. When the blood cell flocculant 8 contains a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as a cationic polymer, the blood cell flocculant 8 may be used. , Any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate, or any combination of two or more. You may be. Further, the quaternary ammonium salt homopolymer may be used alone or in combination of two or more. Similarly, the quaternary ammonium salt copolymer may be used alone or in combination of two or more. Similarly, as the quaternary ammonium salt polycondensate, one type may be used alone or two or more types may be used in combination. In addition, in this specification, "hemagglutination agent" expresses erythrocyte aggregation by a single compound capable of agglutinating blood erythrocytes, a plurality of combinations of the single compound, or a combination of a plurality of compounds. It is an agent that produces red blood cells. That is, the hemagglutination agent is an agent limited to those having a hemagglutination action. Therefore, when the hemagglutination agent contains a third component, it is expressed as a hemagglutination agent composition to distinguish it from the hemagglutination agent. The term "single compound" as used herein is a concept that includes compounds having the same composition formula but different molecular weights due to different numbers of repeating units.

Among the various cationic polymers described above, the use of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate is particularly effective in terms of adsorptivity to erythrocytes. preferable. In the following description, for the sake of simplicity, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer, and the quaternary ammonium salt polycondensate are collectively referred to as "quaternary ammonium salt polymer".

The quaternary ammonium salt homopolymer is obtained by using one kind of polymerizable monomer having a quaternary ammonium moiety and polymerizing the polymerizable monomer. On the other hand, the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more kinds of polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or a quaternary ammonium moiety is used. It is obtained by copolymerizing one or more polymerizable monomers having one or more and one or more polymerizable monomers having no quaternary ammonium moiety. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by polymerizing the condensate using one or more monomers having a quaternary ammonium moiety. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing two or more types of monomers having a quaternary ammonium moiety and polymerizing them, or a quaternary ammonium moiety. It is obtained by polycondensation of one or more monomers having the above and one or more monomers having no quaternary ammonium moiety.

The quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety. The quaternary ammonium moiety can be generated by quaternary ammonium conversion of a tertiary amine with an alkylating agent. Alternatively, the tertiary amine can be dissolved in an acid or water and neutralized. Alternatively, it can be produced by quaternary ammonium conversion by a nucleophilic reaction including a condensation reaction. Examples of the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate. Of these alkylating agents, dialkyl sulfate is preferable because it does not cause the problem of corrosion that may occur when alkyl halide is used. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, hyaluronic acid and the like. .. In particular, it is preferable to use a quaternary ammonium salt polymer in which the tertiary amine moiety is quaternary ammonium-modified with an alkylating agent because the electric double layer of erythrocytes can be reliably neutralized. Tertiary ammonium conversion by a nucleophilic reaction including a condensation reaction can occur as in a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin, and a cyclization reaction of dicyandiamide and diethylenetriamine.

As a result of the study by the present inventor, it has been found that the use of a cationic polymer is particularly effective for producing erythrocyte aggregates in menstrual blood. The reason for this is as follows. Red blood cells have an erythrocyte membrane on their surface. The erythrocyte membrane has a two-layer structure. This two-layer structure consists of a lower layer, the erythrocyte membrane skeleton, and an upper layer, the lipid film. The lipid film exposed on the surface of red blood cells contains a protein called glycophorin. Glycophorin has a sugar chain at the end of which an anion-charged sugar called sialic acid is bound. As a result, erythrocytes can be treated as anionic-charged colloidal particles. A flocculant is generally used for agglomeration of colloidal particles. Considering that erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as the flocculant from the viewpoint of neutralizing the electric double layer of erythrocytes. Further, when the flocculant has a polymer chain, the polymer chains of the flocculant adsorbed on the surface of the erythrocytes are likely to be entangled with each other, which promotes the aggregation of erythrocytes. Further, when the flocculant has a functional group, the interaction between the functional groups also promotes the aggregation of erythrocytes, which is preferable.

From the viewpoint of effectively producing agglomerates of erythrocytes, the molecular weight of the cationic polymer is preferably 2000 or more, more preferably 10,000 or more, and further preferably 30,000 or more. When the molecular weight of the cationic polymer is equal to or higher than these values, entanglement of the cationic polymers between erythrocytes and cross-linking of the cationic polymers between erythrocytes are sufficiently caused. The upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less. When the molecular weight of the cationic polymer is less than or equal to these values, the cationic polymer dissolves well in menstrual blood. The molecular weight of the cationic polymer is preferably 20 or more and 10 million or less, more preferably 20 or more and 5 million or less, further preferably 20 or more and 3 million or less, and 10,000 or more and 3 million or less. It is even more preferable, and it is particularly preferable that it is 30,000 or more and 3 million or less. The molecular weight referred to in the present invention is a weight average molecular weight. The molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions thereof. The molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. The specific measurement conditions are as follows. As the column, a guard column α manufactured by Tosoh Corporation and an analysis column α-M connected in series are used at a column temperature of 40 ° C. RI (refractive index) is used as the detector. As a measurement sample, 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent. For the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, an eluent in which 150 mmol / L sodium sulfate and 1% by mass of acetic acid are dissolved in water is used. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900 pullulan, a molecular weight of 47300 pullulan, a molecular weight of 212,000 pullulan, and a molecular weight of 788,000 per 10 mL of the eluent. Pullulan, a mixture of pullulan in which 2.5 mg each is dissolved, is used as a molecular weight standard. The copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection volume of 100 μL. Except for copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate, elution of 50 mmol / L lithium bromide and 1% by mass of acetic acid in ethanol: water = 3: 7 (volume ratio). Use liquid. Except for copolymers containing water-soluble polymerizable monomers such as hydroxyethyl methacrylate, polyethylene glycol (PEG) having a molecular weight of 106, PEG having a molecular weight of 400, PEG having a molecular weight of 1470, and PEG having a molecular weight of 6450 per 20 mL of eluent. , Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a mixture of PEG-PEO in which 10 mg each is dissolved are used as the molecular weight standard. Except for the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the measurement is carried out at a flow rate of 0.6 mL / min and an injection amount of 100 μL.

When a quaternary ammonium salt polymer is used as the cationic polymer from the viewpoint of more effectively producing erythrocyte aggregates, the flow potential of the quaternary ammonium salt polymer is preferably 1500 μeq / L or more. , 2000 μeq / L or more, more preferably 3000 μeq / L or more, and even more preferably 4000 μeq / L or more. When the flow potential of the quaternary ammonium salt polymer is equal to or higher than these values, the electric double layer of erythrocytes can be sufficiently neutralized. The upper limit of the flow potential is preferably 13000 μeq / L or less, more preferably 8000 μeq / L or less, and even more preferably 6000 μeq / L or less. When the flow potential of the quaternary ammonium salt polymer is equal to or less than these values, it is possible to effectively prevent the electrical repulsion between the quaternary ammonium salt polymers adsorbed on the erythrocytes. The flow potential of the quaternary ammonium salt polymer is preferably 1500 μeq / L or more and 13000 μeq / L or less, more preferably 2000 μeq / L or more and 13000 μeq / L or less, and 3000 μeq / L or more and 8000 μeq / L or less. More preferably, it is more preferably 4000 μeq / L or more and 6000 μeq / L or less. The flow potential of the quaternary ammonium salt polymer adjusts, for example, the molecular weight of the constituent cationic monomer itself and the copolymer molar ratio of the cationic monomer constituting the copolymer and the anionic monomer or the nonionic monomer. It can be controlled by. The flow potential of the quaternary ammonium salt polymer can be measured using a flow potential measuring device (PCD04) manufactured by Spectris Co., Ltd. The specific measurement conditions are as follows. First, the hot melt that adheres each member to a commercially available napkin is invalidated by using a dryer or the like, and the napkin is decomposed into members such as a front sheet, an absorber, and a back sheet. A multi-step solvent extraction method from a non-polar solvent to a polar solvent is performed on each of the decomposed members, and the treatment agent used for each member is separated to obtain a solution containing a single composition. The obtained solution is dried and solidified, and 1H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel). Permeation chromatography), fluorescent X-ray, etc. are combined to identify the structure of the treatment agent. 0.001N aqueous sodium polyethylene sulfonate solution (if the measurement sample has a negative charge) with respect to the measurement sample in which 0.001 g of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 10 g of physiological saline. , 0.001N aqueous solution of polydiallyl dimethylammonium chloride) is titrated, and the amount of drops XmL required until the potential difference between the electrodes disappears is measured. Then, the flow potential of the quaternary ammonium salt polymer is calculated by the formula 1.
Flow potential = (X + 0.190 *) × 1000 ・ ・ ・ Equation 1
(* Titration required for physiological saline as a solvent)

In order for the cationic polymer to be successfully adsorbed on the surface of erythrocytes, it is advantageous that the cationic polymer easily interacts with sialic acid present on the surface of erythrocytes. From this point of view, the present inventor proceeded with the study and found that the value of the inorganic value / organic value, which is the ratio of the inorganic value of the substance to the organic value (hereinafter referred to as "IOB (Inorganic Organic Balance) value"). It was found that the degree of interaction between the sialic acid bond and the cationic polymer can be evaluated using the above as a scale. In detail, it has been found that it is advantageous to use a cationic polymer having an IOB value equal to or close to the IOB value of the sialic acid bond. The sialic acid bond is a compound in which sialic acid can exist in a living body, and examples thereof include a compound in which sialic acid is bound to the end of a glycolipid such as a galactolipid.

In general, the properties of a substance are largely controlled by various intermolecular forces between molecules, and this intermolecular force mainly consists of Van Der Waals force due to molecular mass and electrical affinity due to molecular polarity. If the Van Der Waals force, which has a great influence on changes in the properties of substances, and the electrical affinity can be grasped individually, the properties of unknown substances or mixtures thereof can be predicted from the combination. be able to. This idea is a well-known theory as "organic conceptual diagram". For example, "Organic Analysis" by Akira Fujita (Kaniya Shoten, Showa 5), "Organic Qualitative Analysis: Systematic. Pure Product Edition" by Akira Fujita (Kyoritsu Publishing, 1953), Akira Fujita "Reorganized Chemical Experiments-Organic Chemistry" (Kawade Shobo, 1971), "Systematic Organic Qualitative Analysis (Mixed)" by Akira Fujita and Masami Akatsuka (Kazama Shobo, 1974), and Yoshio Koda. It is described in detail in "New Edition Organic Conceptual Diagram Basics and Applications" (Sankyo Publishing, 2008) by Shiro Sato and Yoshio Homma. In the physicochemical properties of substances, the degree of physical properties mainly due to Van Der Waals force is called "organic", and the degree of physical properties mainly due to electrical affinity is called "inorganic". It captures the physical properties of substances as a combination of "organic" and "inorganic". Then, one carbon (C) is defined as organic 20, and the inorganic and organic values of various polar groups are defined as shown in Table 1 below, and the sum of the inorganic values and the organic value are defined. The sum of the values is calculated, and the ratio of the two is defined as the IOB value. In the present invention, the IOB value of the above-mentioned sialic acid bond is determined based on these organic and inorganic values, and the IOB value of the cationic polymer is determined based on the value.

Specifically, when the cationic polymer is a homopolymer, the inorganic value and the organic value are determined based on the repeating unit of the homopolymer, and the IOB value is calculated. For example, in the case of polydiallyldimethylammonium chloride, which is a cationic polymer, an organic value of −C− × 8 = 160, an inorganic value of Ammo and NH4 salt × 1 = 400, and a Ring (non-aromatic single ring). Since it has an inorganic value of × 1 = 10, an organic value of −Cl × 1 = 40, and an inorganic value of 10, the total of the inorganic values is 400 + 10 + 10 = 420, and the total of the organic values is 160 + 40. = 200. Therefore, the IOB value is 420/200 = 2.10.

On the other hand, when the cationic polymer is a copolymer, the IOB value is calculated by the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, the copolymer is obtained from the monomer A and the monomer B, the organic value of the monomer A is ORA, the inorganic value is INA, the organic value of the monomer B is ORB, and the inorganic value is INB. If there is, and the molar ratio of monomer A / monomer B is MA / MB, the IOB value of the copolymer is calculated from the following formula.

The IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, further preferably 2.1 or more, and 2.2. The above is more preferable. The IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, and 2.1 or more and 3.6 or less. It is more preferable that it is 2.2 or more and 3.0 or less. The IOB value of sialic acid is 4.25 for sialic acid alone and 3.89 for sialic acid conjugate. The sialic acid conjugate is a bond of a sugar chain and sialic acid in a glycolipid, and the sialic acid conjugate has a higher proportion of organic values and a lower IOB value than sialic acid alone.

As described above, the IOB value of the cationic polymer is preferably 40 or more, more preferably 100 or more, and further preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, further preferably 240 or less, and even more preferably 190 or less. For example, the organic value is preferably 40 or more and 310 or less, more preferably 40 or more and 250 or less, further preferably 100 or more and 240 or less, and further preferably 130 or more and 190 or less. By setting the organic value of the cationic polymer in this range, the cationic polymer is more successfully adsorbed on the red blood cells.

On the other hand, regarding the inorganic value of the cationic polymer, it is preferably 70 or more, more preferably 90 or more, further preferably 100 or more, further preferably 120 or more, and 250 or more. Is particularly preferable. Further, it is preferably 790 or less, further preferably 750 or less, further preferably 700 or less, further preferably 680 or less, and particularly preferably 490 or less. For example, the inorganic value is preferably 70 or more and 790 or less, more preferably 90 or more and 750 or less, further preferably 90 or more and 680 or less, and further preferably 120 or more and 680 or less. It is particularly preferable that it is 250 or more and 490 or less. By setting the inorganic value of the cationic polymer in this range, the cationic polymer is more successfully adsorbed on the red blood cells.

From the viewpoint of even more successfully adsorbing the cationic polymer to erythrocytes, when the organic value of the cationic polymer is x and the inorganic value is y, it is preferable that x and y satisfy the following formula A.
y = ax (A)
In the formula, a is preferably 0.66 or more, more preferably 0.93 or more, and even more preferably 1.96 or more. Further, a is preferably 4.56 or less, more preferably 4.19 or less, and further preferably 3.5 or less. For example, a is preferably a number of 0.66 or more and 4.56 or less, more preferably 0.93 or more and 4.19 or less, and a number of 1.96 or more and 3.5 or less. Is more preferable. In particular, if the organic value and the inorganic value of the cationic polymer satisfy the above formula A, provided that the organic value and the inorganic value of the cationic polymer are within the above ranges, the cation The sex polymer is more likely to interact with the sialic acid conjugate, and the cationic polymer is even more likely to be adsorbed on erythrocytes.

From the viewpoint of effectively producing erythrocyte aggregates, the cationic polymer is preferably water-soluble. In the present invention, "water-soluble" means that 0.05 g of a powdered cationic polymer having a thickness of 1 mm or less or a film-like cationic polymer having a thickness of 0.5 mm or less is added to and mixed with 50 mL ion-exchanged water at 25 ° C. in a 100 mL glass beaker (5 mmΦ). When this is done, a stirrer chip having a length of 20 mm and a width of 7 mm is inserted, and the entire amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by AS ONE Corporation. In the present invention, as the more preferable solubility, the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.

The cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. The quaternary ammonium moiety is preferably present in the side chain. In this case, if the main chain and the side chain are bonded at one point, the flexibility of the side chain is less likely to be inhibited, and the quaternary ammonium site present in the side chain is smoothly applied to the surface of the erythrocyte. It will be adsorbed. However, in the present invention, it is not prevented that the main chain and the side chain of the cationic polymer are bonded at two points or more. In the present invention, "bonded at one point" means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain. .. "Bonded at two or more points" means that two or more of the carbon atoms constituting the main chain are single-bonded with two or more carbon atoms located at the ends of the side chains. Say.

When the cationic polymer has a structure having a main chain and a plurality of side chains bonded to the main chain, for example, a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded to the main chain. In the case of, the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more. The upper limit of the number of carbon atoms is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less. For example, the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and further preferably 6 or more and 8 or less. The carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cationic moiety) in the side chain, and even if carbon is contained in the anion which is a counterion, the carbon is counted. Not included. In particular, among the carbon atoms in the side chain, the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is within the above range. It preferred because sterically hindered becomes lower when the polymer is adsorbed on the front surface of red blood cells.

When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, examples of the homopolymer include polymers of vinyl-based monomers having a quaternary ammonium moiety or a tertiary amine moiety. .. When polymerizing a vinyl-based monomer having a tertiary amine moiety, a quaternary ammonium salt homozygous in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization. It becomes a polymer, a tertiary amine neutralized salt in which the tertiary amine moiety is neutralized with an acid before and / or after polymerization, or a tertiary amine that takes a cation in an aqueous solution after polymerization. .. Examples of alkylating agents and acids are as described above.

In particular, the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.

Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine and the like. In addition, poly (2-methacryloxyethyl dimethylamine quaternary salt) and poly (2-methacryloxyethyl trimethylammonium salt) in which the side chain having a quaternary ammonium moiety is bonded to the main chain at one point. ), Poly (2-methacryloxyethyl dimethyl ethyl ammonium methyl sulfate), poly (2-acrylic oxyethyl dimethylamine quaternary salt), poly (2-acrylic oxyethyl trimethylamine quaternary salt), poly (2-acrylic oxy) Ethyldimethylethylammonium ethyl sulfate), poly (3-dimethylaminopropylacrylamide quaternary salt), dimethylaminoethyl polymethacruate, polyallylamine hydrochloride, cationized cellulose, polyethyleneimine, polydimethylaminopropylacrylamide, polyamidine, etc. Be done. On the other hand, examples of homopolymers in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydialylamine hydrochloride.

When the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, two kinds of polymerizable monomers used for the polymerization of the above-mentioned quaternary ammonium salt homopolymer are used as the copolymer. The copolymer obtained by the above-mentioned copolymerization can be used. Alternatively, as the quaternary ammonium salt copolymer, one or more polymerizable monomers used for the polymerization of the above-mentioned quaternary ammonium salt homopolymer and a polymerizable single amount having no quaternary ammonium moiety. A copolymer obtained by copolymerizing with one or more bodies can be used. Further, in addition to or in place of the vinyl-based polymerizable monomer, another polymerizable monomer such as −SO ₂₋ can be used. As described above, the quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer.

In particular, the quaternary ammonium salt copolymer having a repeating unit represented by the above formula 1 and a repeating unit represented by the following formula 2 effectively produces agglomerates of erythrocytes. Preferred from the point of view.

Further, as the polymerizable monomer having no quaternary ammonium moiety, a cationically polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. Among these polymerizable monomers, by using a cationically polymerizable monomer or a nonionic polymerizable monomer, charge cancellation with the quaternary ammonium moiety in the quaternary ammonium salt copolymer is performed. Can be effectively caused by the aggregation of red blood cells. Examples of cationically polymerizable monomers include vinylpyridine as a cyclic compound having a cation-bearing nitrogen atom under specific conditions, and a linear compound having a cation-bearing nitrogen atom in the main chain under specific conditions. Examples thereof include a condensed compound of dicyandiamide and diethylenetriamine. Examples of anionic polymerizable monomers include 2-acrylamide-2-methylpropanesulfonic acid, methacrylic acid, acrylic acid, styrenesulfonic acid, and salts of these compounds. On the other hand, examples of nonionic polymerizable monomers include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate and methyl. Examples thereof include acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate and butyl acrylate. As these cationically polymerizable monomer, anionic polymerizable monomer, or nonionic polymerizable monomer, one of them can be used, or any two or more kinds can be used in combination. Can be done. Further, two or more kinds of cationically polymerizable monomers can be used in combination, two or more kinds of anionic polymerizable monomers can be used in combination, or two or more kinds of nonionic polymerizable monomers can be used in combination. Can also be used. The quaternary ammonium salt copolymer copolymerized by using a cationically polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight thereof. However, as described above, it is preferably 10 million or less, particularly preferably 5 million or less, particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of hydrogen bonding can also be used. When such a polymerizable monomer is used for copolymerization, and when erythrocytes are agglutinated using a quaternary ammonium salt copolymer obtained from the copolymer, hard agglutination is likely to occur, and the highly absorbent polymer Absorption performance is less likely to be impaired. Examples of functional groups capable of hydrogen bonding include -OH, -NH ₂ , -CHO, -COOH, -HF, and -SH. Examples of polymerizable monomers having a functional group capable of hydrogen bonding include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethyl acrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, and ethylene glycol monoacrylate. Examples thereof include hydroxyethyl methacrylate and hydroxyethyl acrylate. In particular, hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide and the like, in which hydrogen bonds work strongly, are preferable because the adsorption state of the quaternary ammonium salt polymer to erythrocytes is stabilized. These polymerizable monomers may be used alone or in combination of two or more.

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of having a hydrophobic interaction can also be used. By using such a polymerizable monomer for copolymerization, the same advantageous effect as the case of using the above-mentioned polymerizable monomer having a functional group capable of hydrogen bonding, that is, the hardness of erythrocytes is obtained. The effect is that agglomerates are likely to occur. Examples of the functional group capable of having a hydrophobic interaction include an alkyl group such as a methyl group, an ethyl group and a butyl group, a phenyl group, an alkylnaphthalene group and an alkylfluoride group. Examples of polymerizable monomers having a functional group capable of having a hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, and styrene. Can be mentioned. In particular, methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc., which have strong hydrophobic interactions and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are in the state of adsorption of the quaternary ammonium salt polymer to red blood cells. Is preferable because it stabilizes. These polymerizable monomers may be used alone or in combination of two or more.

The molar ratio of the polymerizable monomer having a quaternary ammonium moiety to the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary. It is preferable that the ammonium salt copolymer is appropriately adjusted so that the erythrocytes are sufficiently aggregated. Alternatively, it is preferable that the flow potential of the quaternary ammonium salt copolymer is adjusted to the above-mentioned value. Alternatively, it is preferable that the IOB of the quaternary ammonium salt copolymer is adjusted to the above-mentioned value. In particular, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. It is more preferably% or more, and even more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, further preferably 65 mol% or less, and further preferably 56 mol% or less. Specifically, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, and more preferably 22 mol% or more and 80 mol% or less. It is more preferably 32 mol% or more and 65 mol% or less, and further preferably 38 mol% or more and 56 mol% or less.

When the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, a condensate composed of one or more monomers having the above-mentioned quaternary ammonium moiety is used as the polycondensate. The polycondensate obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.

The above-mentioned quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or a copolymerization method of a vinyl-based polymerizable monomer. As the polymerization method, for example, radical polymerization, living radical polymerization, living cationic polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used. The polymerization conditions are not particularly limited, and the conditions for obtaining a quaternary ammonium salt polymer having a target molecular weight, flow potential, and / or IOB value may be appropriately selected.

The cationic polymer described in detail above is an example of the above-mentioned "favorable hemagglutination agent 8", and its effect can be referred to in Examples 1 to 45 of Japanese Patent Application No. 2015-239286.

Further, as the hemagglutination agent 8 included in the napkin 1, as described above, a composition containing a third component, for example, a solvent, a plasticizer, a fragrance, a skin care agent, etc., in addition to the polycation (cationic polymer). It may be given in the form of a hemagglutination agent composition). In addition, one or more components other than the cationic polymer that can be contained in the hemagglutination agent 8 can be mixed. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used. As the fragrance, a fragrance having a green herbal-like fragrance, a plant extract, a citrus extract, etc. described in Japanese Patent No. 4776407 can be used. As the skin care agent, plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in Japanese Patent No. 4084278 can be used.

The proportion of the cationic polymer in the hemagglutination composition is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and further preferably 10% by mass or less. For example, the proportion of the cationic polymer is preferably 1% by mass or more and 50% by mass or less, more preferably 3% by mass or more and 30% by mass or less, and further preferably 5% by mass or more and 10% by mass or less. preferable. By setting the proportion of the cationic polymer in the hemagglutination composition within this range, an effective amount of the cationic polymer can be imparted to the physiologically absorbent article.

As described above, in the napkin 1, as shown in FIGS. 3 and 4, the hemagglutination agent 8 is arranged on the second sheet 5 and the absorber 4. The blood cell flocculant 8 is present on the non-skin facing surface side of the second sheet 5 in contact with the absorber 4, and at least on the non-skin facing surface side of the second sheet 5 on the skin facing surface side of the second sheet 4 in contact with the second sheet 5. In the napkin 1, they are present on the non-skin facing surface side of the second sheet 5 and the skin facing surface side of the absorber 4. The amount of the hemagglutin 8 contained in the second sheet 5 is preferably 0.1 g / m ² or more, more preferably 0.5 g / m ² or more, and 1.5 g / m ² or more. It is more preferable to have. Further, it is preferably 25 g / m ² or less, more preferably 15 g / m ² or less, and even more preferably 10 g / m ² or less. For example, the amount of the blood cell flocculant 8 in the second sheet 5 is preferably 0.1 g / m ² or more and 25 g / m ² or less, and more preferably 0.5 g / m ² or more and 15 g / m ² or less. It is more preferably 1.5 g / m ² or more and 10 g / m ² or less. By applying the hemagglutination agent 8 to the second sheet 5 in an amount in this range, the excreted menstrual red blood cells can be effectively aggregated. It is particularly preferable that the hemagglutination agent 8 is a cationic polymer and the amount of the cationic polymer contained in the second sheet 5 is in the above range.

In the napkin 1, the hemagglutin 8 is present on the non-skin facing surface side NT in contact with the absorber 4 in the second sheet 5 and the skin facing surface side HT in contact with the surface sheet 2 in the second sheet 5, and is present on the skin facing surface side HT. It is present more in the non-skin facing surface side NT than in the surface side HT. Here, "many exist" means that the second sheet 5 is divided into two equal parts in the thickness direction Z, and one piece of the non-skin facing surface side NT and the other piece of the skin facing surface side HT are each divided into two equal parts. When comparing the mass of the antibacterial agent 43 existing per area, that is, the basis weight of the antibacterial agent 43 in each piece, the basis weight of the antibacterial agent 43 of one piece of NT on the non-skin facing surface side is relatively large. Means.

Whether or not the hemagglutination agent 8 is arranged on the second sheet 5 can be easily analyzed by those skilled in the art, such as a method of exposing the second sheet to a solvent to perform an extraction operation and then analyzing the extracted components. For example, it can be determined as follows.
Using an energy dispersive X-ray analyzer (EDX) attached to a scanning electron microscope (SEM), elemental analysis of each of the fibers 51 and the hemagglutination agent 8 constituting the second sheet 5 is performed in advance. Next, a sample piece for which it is desired to determine whether or not the hemagglutination agent 8 is arranged is attached to an aluminum sample table using a carbon double-sided tape, and if necessary, platinum / vanadium coating is applied, and then SEM observation is performed. The presence or absence of the element of the hemagglutination agent 8 is confirmed using EDX (elemental analyzer) while expanding with. The measurement is performed at an accelerating voltage of 15 kV to 40 kV.

Further, whether or not the blood cell flocculant 8 is present in the non-skin facing surface side NT in the second sheet 5 more than in the skin facing surface side HT is determined by the energy dispersive X-ray beam attached to the scanning electron microscope (SEM). The skin facing surface side HT and the non-skin facing surface side NT of the second sheet 5 are measured using an analyzer (EDX), and the amount of the element detected at each position is semi-quantitatively based on the detected element peak information. to decide. If the amount of the element of the hemagglutination agent 8 detected in the non-skin facing surface side NT of the second sheet 5 is larger than that of the skin facing surface side HT, it is present in the non-skin facing surface side NT more than the skin facing surface side HT in the second sheet 5. Judge that you are doing.

Further, the second sheet 5 in which the blood cell flocculant 8 is present in the non-skin facing surface side NT more than the skin facing surface side HT has a portion that becomes the non-skin facing surface side NT in the manufacturing process of the second sheet 5. It can be prepared by selectively containing a hemagglutination agent. For example, during the manufacturing process of the second sheet 5 or after the manufacturing of the second sheet 5, the second sheet 5 is manufactured while spraying or coating the blood cell flocculant 8 from the surface side that becomes the non-skin facing surface side NT to face the skin. It is possible to allow more hemagglutination agent 8 to be present in the non-skin facing surface side NT than in the surface side HT.

The thickness of the second sheet 5 is preferably 0.1 mm or more, particularly 5 mm or more, and preferably 4 mm or less, particularly 3 mm or less. More specifically, 0.1 mm or more and 5 mm or less, particularly 0.1 mm or more and 3 mm or less is preferable from the viewpoint of allowing menstrual blood to permeate in a spot and obtaining a sanitary absorbent article having a good wearing feeling. .. The thickness of the second sheet 5 is measured by the following method.

<Measuring method of the thickness of the second sheet>
Place the second sheet, which is the object to be measured, on a horizontal surface without wrinkles or bends, and measure the thickness under a load of 5 cN / cm ² . A thickness meter PEACOCK DIAL UPRIGHT GAUGES R5-C (manufactured by OZAKI MFG.CO.LTD.) Was used for the thickness measurement in the present invention. At this time, a circular or square plate (acrylic plate with a thickness of about 5 mm) in a plan view is arranged between the tip of the thickness gauge and the measurement portion of the object to be measured, and the load is 5 cN / cm ² . Adjust the size of the plate so that it becomes.

When the absorber 4 contains the blood cell flocculant 8 as in the napkin 1, the amount of the blood cell flocculant 8 contained in the absorber 4 is preferably 0.1 g / m ² or more, and is 0. further preferably .5g / m ² or more, and more preferably 1.5 g / m ² or more. Further, it is preferably 25 g / m ² or less, more preferably 15 g / m ² or less, and even more preferably 10 g / m ² or less. For example, the amount of the hemagglutin 8 contained in the absorber 4 is preferably 0.1 g / m ² or more and 25 g / m ² or less, and 0.5 g / m ² or more and 15 g / m ² or less. More preferably, it is 1.5 g / m ² or more and 10 g / m ² or less. By applying the hemagglutination agent 8 to the absorber 4 in an amount within this range, the excreted menstrual red blood cells can be effectively aggregated. When the hemagglutination agent 8 is applied to two or more sites of the absorber 4, for example, when it is applied to both the main body absorbing sheet 401 and the central absorbing sheet 402, which will be described later, the above-mentioned case. The amount is the sum of the blood cell flocculants 8 applied to each site. It is particularly preferable that the hemagglutination agent 8 is a cationic polymer and the amount of the cationic polymer contained in the absorbent sheet is in the above range.

In the napkin 1, the absorber 4 has a multilayer structure formed of an absorbent sheet as shown in FIGS. 2 and 3. Here, the formed multilayer structure may be formed by stacking a plurality of absorbent sheets, or may be formed by folding one absorbent sheet. However, it may be formed by combining these. In the napkin 1, as shown in FIGS. 2 and 3, the absorber 4 has a central absorbent sheet 402 formed of an absorbent sheet on the excretion portion facing portion B which is arranged to face the excretion portion of the wearer when worn. It is composed of a main body absorbent sheet 401 that covers the central absorbent sheet 402. That is, the absorber 4 of the napkin 1 has a multilayer structure composed of the main body absorbent sheet 401 and the central absorbent sheet 402, and the middle and high portions 403 are formed on the excretion portion facing portion B. The multi-layer structure of the absorber 4 of the napkin 1 has a structure in which the central absorbent sheet 402 is enclosed inside the folding structure of one main body absorbent sheet 401, and the central absorbent sheet 402 is included in the middle and high portions 403. It is arranged.

Preferably, in the napkin 1, as shown in FIGS. 2 and 3, the main body absorbing sheet 401 is composed of one sheet having a length (width) in the lateral direction Y longer than that of the napkin 1, and the main body absorbing sheet 401. Both sides of the sex sheet 401 along the vertical direction X are folded back toward the back surface sheet 3 to form a two-layer structure, and both side edges along the vertical direction X are overlapped at the center of the horizontal direction Y to form the absorber 4. It forms the outer shape. The main body absorbent sheet 401 forming the two-layer structure in this way has a front surface side absorbent sheet 401a on the front surface sheet 2 side and a back surface side absorbent sheet 401b on the back surface sheet 3 side. The central absorbent sheet 402 is composed of one sheet having a rectangular shape in a plan view, and has a three-layer structure in which the central absorbent sheet 402 is folded in three in the lateral direction Y. When the central absorbent sheet 402 has a three-layer structure, the two bending lines crossing the central absorbent sheet 402 in the vertical direction X are set to the second bending line counting from the free end in the horizontal direction Y. Then, fold it toward the back sheet 3 side, and further fold it toward the front sheet 2 side at the first bending line counting from the free end in the lateral direction Y so that the free end in the lateral direction Y is arranged inside the three-layer structure. Fold it in a spiral shape. The central absorbent sheet 402 that forms a three-layer structure that is spirally folded in three is the upper absorbent sheet 402a on the front side absorbent sheet 401a side and the lower absorbent sheet 402 on the back surface side absorbent sheet 401b side. It has a 402b and an intermediate absorbent sheet 402c between those sheets 402a, 402b. The middle and high portion 403 is formed by sandwiching a sheet having a three-layer structure composed of an upper absorbent sheet 402a, an intermediate absorbent sheet 402c and a lower absorbent sheet 402b between a front absorbent sheet 401a and a back absorbing sheet 401b. Has been done. The middle-high portion 403 is formed only in the excretion portion facing portion B, and is not formed in the front portion A and the rear portion C. As shown in FIG. 3, the number of laminated absorbent sheets forming the absorber 4 around the middle and high portion 403 is two, whereas the number of laminated absorbent sheets forming the absorber 4 in the middle and high portion 403 is two. However, the number of laminated sheets is as large as 5, which is a thick part. Therefore, the middle-high portion 403 is a raised portion protruding from the excretion portion facing portion B toward the surface sheet 2 side (the skin facing surface side of the napkin 1).

The thickness of one absorbent sheet is preferably 0.1 mm or more, particularly 0.3 mm or more, and preferably 2 mm or less, particularly 1.5 mm or less. More specifically, a sanitary absorbent article having a size of 0.1 mm or more and 2 mm or less, particularly 0.3 mm or more and 1.5 mm or less, allows menstrual blood to be spot-absorbed by the absorber 4 and has a good fit. It is preferable from the viewpoint of obtaining.

The thickness of the absorber 4 at the middle and high portion 403 is preferably 0.7 mm or more, more preferably 1 mm or more, preferably 5 mm or less, still more preferably 4 mm or less, and more specifically, preferably. It is 0.7 mm or more and 5 mm or less, more preferably 1 mm or more and 4 mm or less. By setting the thickness of the middle-high portion 403 within such a range, it becomes easy to achieve both a good fit and high absorption performance in the excretion portion facing portion B in which the middle-high portion 403 is formed. Further, when the sanitary absorbent article is provided with a wing portion as in the napkin 1 of the present embodiment, it becomes easy to suppress the twist of the absorber at the portion facing the excretion portion at the time of wearing. The thickness of the absorber in the portion other than the middle and high portion 403 is preferably 0.3 mm or more, more preferably 0.5 mm or more, and preferably 3 mm or less, further preferably 2.5 mm or less. More specifically, it is preferably 0.3 mm or more and 3 mm or less, and more preferably 0.5 mm or more and 2.5 mm or less. This range is preferable from the viewpoint of improving the high absorption performance and the ability to follow the movement of the wearer. The thickness of the absorber and the absorbent sheet is measured by the following method.

<Measuring method of thickness of absorbent sheet and absorber>
The absorbent sheet or absorber, which is the object to be measured, is placed on a horizontal surface so as not to be wrinkled or bent, and the thickness under a load of 5 cN / cm ² is measured. A thickness meter PEACOCK DIAL UPRIGHT GAUGES R5-C (manufactured by OZAKI MFG.CO.LTD.) Was used for the thickness measurement in the present invention. At this time, a circular or square plate (acrylic plate with a thickness of about 5 mm) in a plan view is arranged between the tip of the thickness gauge and the measurement portion of the object to be measured, and the load is 5 cN / cm ² . Adjust the size of the plate so that it becomes.

Then, in the napkin 1, as shown in FIG. 3, the absorber 4 made of the absorbent sheet has a portion used by arranging the fiber-rich region FT on the skin-facing surface side. In such a portion where the fiber-rich region FT is arranged on the skin-facing surface side and used, the hemagglutination agent 8 is present at least in the fiber-rich region FT. Here, when the absorber 4 has a multi-layer structure formed of an absorbent sheet like the napkin 1, the hemagglutination agent 8 may be arranged on all the absorbent sheets forming the multi-layer structure. , The hemagglutination agent 8 may not be arranged on all the absorbent sheets. In the napkin 1, as shown in FIG. 4, the hemagglutination agent 8 is arranged on the main body absorbent sheet 401 forming a two-layer structure composed of the front surface side absorbent sheet 401a and the back surface side absorbent sheet 401b. As described above, since the main body absorbent sheet 401 has a two-layer structure in which both sides along the vertical direction X are folded back, the surface side absorbent sheet 401a arranges the fiber rich region FT on the skin facing surface side. The back surface side absorbent sheet 401b is used by arranging the fiber rich region FT on the non-skin facing surface side. Therefore, in the middle and high portion 403, the surface side absorbing sheet 401a, the upper absorbing sheet 402a, and the intermediate absorbing sheet 402c are all in the order of the fiber-rich region FT and the polymer-rich region PT when viewed from the skin contact surface side. In both the lower absorbent sheet 402b and the back surface absorbent sheet 401b, the polymer-rich region PT and the fiber-rich region FT are arranged in this order when viewed from the skin contact surface. Then, in the surface-side absorbent sheet 401a used by arranging the fiber-rich region FT on the skin-facing surface side, the hemagglutination agent 8 is present in the polymer-rich region PT and the fiber-rich region FT, and the polymer-rich region FT is present. It is abundant in the fiber-rich region FT on the skin-facing surface side of the PT. Here, "existing a lot" means comparing the mass of the hemagglutin 8 existing per the area of each region FT and PT, that is, the basis weight of the hemagglutin 8 in each region FT and PT. This means that the basis weight of the hemagglutin 8 in one region is relatively large. As described above, the hemagglutination agent 8 is present on the skin-facing surface side of the absorber 4 in contact with the second sheet 5. In the napkin 1, the hemagglutination agent 8 is not arranged on the central absorbent sheet 402 that forms a three-layer structure composed of the upper absorbent sheet 402a, the intermediate absorbent sheet 402c, and the lower absorbent sheet 402b.

Further, in the back surface side absorbent sheet 401b in which the fiber rich region FT is arranged on the non-skin facing surface side, in other words, the polymer rich region PT is arranged on the skin facing surface side and used, hemagglutination The agent 8 is present in the polymer-rich region PT and the fiber-rich region FT, and is more abundant in the fiber-rich region FT than in the polymer-rich region PT.

Whether or not the hemagglutination agent 8 is arranged in the absorber 4 is determined as follows.
Using the energy dispersive X-ray analyzer (EDX) attached to the scanning electron microscope (SEM), the highly absorbent polymer 41 of the absorber 4, the synthetic fiber 46 of the absorber 4, and the cellulosic fiber 47 are used in advance. , And blood cell flocculant 8, each elemental analysis is performed. Next, a sample piece for which it is desired to determine whether or not the hemagglutination agent 8 is arranged is attached to an aluminum sample table using a carbon double-sided tape, and if necessary, platinum / vanadium coating is applied, and then SEM observation is performed. The presence or absence of the element of the hemagglutination agent 8 is confirmed using EDX (elemental analyzer) while expanding with. The measurement is performed at an accelerating voltage of 15 kV to 40 kV.

Further, whether or not the hemagglutination agent 8 is present in the fiber-rich region FT more than the polymer-rich region PT is semi-quantitatively determined as follows.
A sample piece made of an absorbent sheet having a polymer-rich region PT and a fiber-rich region FT and containing a blood cell flocculant 8 is attached to an aluminum sample table using a carbon double-sided tape, and platinum is used as necessary. / After vanadium coating, using EDX (elemental analyzer) while magnifying by SEM observation, elemental mapping of highly absorbent polymer 41, elemental mapping of synthetic fiber 46 and cellulosic fiber 47, blood cell flocculant Mapping of 8 elements is performed. The measurement is performed at an accelerating voltage of 15 kV to 40 kV. Then, comparing the obtained element distribution mappings, the element mapping of the blood cell flocculant 8 is more similar to the element mapping of the synthetic fiber 46 and the cellulosic fiber 47 than the element mapping of the highly absorbent polymer 41. If so, it is determined that the blood cell flocculant 8 is present in the fiber-rich region FT more than in the polymer-rich region PT.

Further, the absorbent sheet in which the blood cell flocculant 8 is present in the fiber-rich region FT more than the polymer-rich region PT is selectively selected for the fiber-rich region FT in the process of manufacturing the absorbent sheet. Can be created by including. For example, when the absorbent sheet has a structure in which a fiber-rich layer having a fiber-rich region FT and a polymer-rich layer having a polymer-rich region PT are superposed on each of the upper and lower layers, the layers are prepared separately. The fiber-rich layer may contain the blood cell flocculant 8 before being superposed on the polymer-rich layer.

For example, the case of the absorbent sheet described in Japanese Patent No. 2963647 will be described. The highly absorbent polymer is sprayed on a wet fiber web made by wet-making a water slurry containing at least synthetic fibers 46 and cellulose-based fibers 47 and a heat-meltable adhesive fiber or a paper strength reinforcing agent. To form a highly absorbent polymer-rich layer (corresponding to the polymer-rich region PT) in which the highly absorbent polymer penetrates between the fibers, and fibers containing synthetic fibers 46 and cellulose-based fibers 47 and heat-meltable adhesive fibers or paper. The fiber aggregates containing the force reinforcing agent are laminated, integrated, and dried to produce an absorbent sheet, whereby the laminated fiber aggregates become a fiber-rich layer (corresponding to the fiber-rich region FT). The hemagglutin 8 is contained in the superposed fiber aggregate in advance, or the absorbent sheet is manufactured while spraying or coating the hemagglutin 8 on the superposed fiber aggregate in the process of manufacturing the absorbent sheet. By doing so, it becomes possible to allow more hemagglutination agent 8 to be present in the fiber-rich layer than in the absorbent polymer-rich layer.
The layer on which the highly absorbent polymer is sprayed is not limited to the wet web, and may be laminated pulp, papermaking, dried paper or non-woven fabric. From the viewpoint that the highly absorbent polymer easily enters between the fibers, bulky paper such as crepe-treated or air-through non-woven fabric is preferable, and the fibers of the high-absorbent polymer and the high-absorbent polymer-rich layer, and the high-absorbency A hot melt, a water-soluble adhesive, or the like may be used as a means for adhering the polymer-rich layer and the fiber-rich layer. Further, the fiber-rich layer may be formed by stacking or spraying fibers containing synthetic fibers 46 and cellulosic fibers 47 on the highly absorbent polymer-rich layer. Further, as a method of applying the hemagglutination agent 8, the hemagglutination agent 8 may be sprayed or coated on the fiber-rich layer side after the absorbent sheet is manufactured.

In the napkin 1, the synthetic fiber 46 constituting the absorber 4 includes a portion of the absorber 4 that is oriented in the thickness direction Z (hereinafter, also referred to simply as a fiber 461 that is oriented in the thickness direction Z). )have. Here, the fiber 461 having a portion oriented in the thickness direction Z has an angle β (see FIG. 4) formed by the virtual line IL1 extending parallel to the thickness direction Z and one synthetic fiber 46 of 45 degrees or less. It means a fiber having a portion that becomes. Preferably, in the napkin 1, the absorber 4 is formed in a multilayer structure composed of the main body absorbent sheet 401 and the central absorbent sheet 402, and the synthetic fiber 46 and the cellulosic fiber 47 constituting the absorber 4 are the main body. It is contained in the absorbent sheet 401 and the central absorbent sheet 402. The synthetic fibers 46 contained in the main body absorbent sheet 401 and the central absorbent sheet 402 each have fibers 461 oriented in the thickness direction Z.

In the napkin 1, the fiber 461 having a portion oriented in the thickness direction Z bisectors the thickness of the absorber 4 with the portion 461U exposed on the skin-facing surface of the absorber 4, as shown in FIG. It is a fiber in which the portion 461D located on the non-skin facing surface side of the absorber 4 is connected by one with the bisector IL2. Here, the "thickness of the absorber 4" means that the absorber 4 is formed by stacking a plurality of absorbent sheets or by folding one absorbent sheet. , Means the thickness of one absorbent sheet constituting the absorber 4, and when the absorber 4 is formed of a fiber-type absorbent core and a core wrap sheet wrapping the absorbent core. , It means the thickness of the state itself in which the absorbent core is wrapped with the core wrap sheet. Further, the portion 461U exposed on the skin facing surface and the portion 461D located on the non-skin facing surface side are not only the portions located at both ends of the fiber 461 but also the intermediate portions located between both ends of the fiber 461. However, the portion may be exposed on the skin-facing surface of the absorber 4, or may be located on the non-skin-facing surface side of the absorber 4 with respect to the bisector IL2. The portion 461D located on the non-skin facing surface side extends further toward the non-skin facing surface side of the absorber 4 than the bisector IL2, and is exposed to the non-skin facing surface of the absorber 4. It is preferable that

The fibers 461 and the hemagglutin 8 having a portion oriented in the thickness direction Z are at least arranged in the excretion portion facing portion B which is arranged to face the excretion portion of the wearer when worn in a plan view. preferable. In the napkin 1, the hemagglutination agent 8 is arranged on the main body absorbent sheet 401 having a two-layer structure constituting the second sheet 5 and the absorber 4, and the fiber 461 having a portion oriented in the thickness direction Z is formed. It is arranged on the main body absorbent sheet 401 and the central absorbent sheet 402 constituting the absorber 4. Therefore, in the napkin 1, the fibers 461 and the hemagglutination agent 8 are arranged not only in the excretion portion facing portion B but also in the entire area from the front portion A to the rear portion C, as shown in FIGS. 1 and 2.

Each component of the napkin 1 of the present embodiment described above will be described.

As the surface sheet 2, a non-woven fabric having a single-layer or multi-layer structure, a perforated film, or the like can be used, but a surface sheet made of a non-woven fabric treated with a hydrophilic agent can be preferably used. As the hydrophilizing agent, various substances conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation. In the napkin 1, the sheet having the uneven structure shown in FIG. 5 is used. FIG. 5 shows an enlarged portion of the surface of the surface sheet 2 facing the skin of the napkin 1. On the skin-facing surface 2a of the surface sheet 2 (skin-facing surface of the napkin 1), recesses 20 extending in directions intersecting each of the vertical direction X and the horizontal direction Y (that is, in the diagonal direction) are formed in an oblique lattice pattern. The surface sheet 2 is partitioned into a large number of regions by the recessed portion 20, and a large number of compartment regions 22 are formed. In the embodiment shown in FIG. 5, the recessed portion 20 is formed over the entire surface of the surface sheet 2. Instead of this, the recessed portion 20 may be formed at least in the excretion portion facing portion B. The X direction in FIG. 5 is the same direction as the direction (CD) orthogonal to the flow direction of the sheet at the time of manufacturing the surface sheet, and is also the same direction as the vertical direction X (see FIG. 1) of the napkin 1. Further, the Y direction in FIG. 5 is the same direction as the sheet flow direction (MD) at the time of manufacturing the surface sheet, and is also the same direction as the lateral direction Y of the napkin 1 (see FIG. 1).

The surface sheet 2 will be further described. The surface sheet 2 is made of a fiber sheet such as a non-woven fabric having a single layer structure or a multi-layer structure, and the entire area of the skin facing surface 2a is formed in an oblique lattice pattern as shown in FIG. It has a concave-convex shape having a large number of recessed portions 20 and convex portions 21 surrounded by the recessed portions 20. On the other hand, the non-skin facing surface 2b of the surface sheet 2 does not substantially have an uneven shape and is substantially flat.

The recessed portion 20 is formed by crimping or adhering the constituent fibers of the surface sheet 2 made of a fiber sheet. Examples of the means for crimping the fibers include squeezing with or without heat, embossing such as ultrasonic squeezing. As a result, in the surface sheet 2, the density of the recessed portion 20 is higher than the density of the convex portion 21. Due to this, the recessed portion 20 tends to act as a deformable flexible shaft when an external force is applied to the surface sheet 2. The recessed portion 20 in the surface sheet 2 according to the present embodiment is formed by heat-embossing the fiber web formed by the card method. In the recessed portion 20, heat-sealing fibers, which are constituent fibers of the surface sheet 2 or the non-woven fabric constituting the surface sheet 2, are integrated by heat-sealing. In the heat-sealing fiber in the recess 20, the heat-sealing component is melted and the fiber morphology is not maintained.

In the surface sheet 2, the recessed portion 20 is formed only in the surface sheet 2, and is not formed in the absorber 4 arranged below the surface sheet 2 and adjacent to the surface sheet 2. Therefore, the surface sheet 2 and the absorber 4 are not joined via the recessed portion 20.

The recess 20 is preferably linear. Here, the “linear” means that the shape of the recess 20 is not limited to a straight line as shown in FIG. 5 in a plan view, but includes a curved line, and each line may be a continuous line, or a rectangle, a square, or a rhombus in a plan view. A large number of recesses (embossed portions) such as circles, circles, and crosses may be connected at substantially no interval to form a continuous line as a whole. "Substantially without spacing" means that the adjacent spacing of the recesses is within 5 mm.

The recessed portions 20 are formed in an oblique lattice pattern as shown in FIG. More specifically, the surface sheet 2 is formed as the recessed portions 20 in parallel with each other and at predetermined intervals with a large number of first linear recessed portions 20a formed in parallel with each other and at predetermined intervals. It has a large number of second linear recesses 20b, and the first linear recesses 20a and the second linear recesses 20b intersect each other at a predetermined angle. Both the first linear recess 20a and the second linear recess 20b extend linearly in a direction (that is, an oblique direction) intersecting each of the vertical direction X and the horizontal direction Y. The width of the first linear recess 20a and the width of the second linear recess 20b may be the same or different. The distance between the first linear depressions 20a and the distance between the second linear depressions 20b may be the same or different.

Each of the compartmentalized regions 22 is a region surrounded by a linear recess 20 and has a rhombic shape in a plan view. Area of each divided area 22 is preferably, for example, 0.25 cm ² or more 2 cm ² or less. The compartment area 22 can have a rhombic shape that is longer in the horizontal direction Y than in the vertical direction X in a plan view. Alternatively, conversely, a rhombus shape that is longer in the vertical direction X than in the horizontal direction Y can be formed. When the partition area 22 has a shape long in the lateral direction Y of the napkin 1, the surface sheet 2 on which a large number of recesses 20 are formed comes to maintain high rigidity in the lateral direction Y. As a result, twisting and wrinkles in the wearing state of the napkin 1 are effectively prevented. The twists and wrinkles in the worn state of the napkin 1 are mainly caused by the fact that the napkin 1 sandwiched between the wearer's thighs is pressed from the lateral direction Y by the thighs. If the napkin 1 maintains high rigidity in the lateral direction Y, the shape of the napkin 1 is easily maintained even when pressed from the lateral direction Y, and twists and wrinkles are less likely to occur.

Each compartment area 22 is formed with a convex portion 21 that rises relative to the recess 20 surrounding the compartment area 22, and each compartment area 22 has a convex portion 21a provided on the skin facing surface 2a side. It has a shape. The top portion 21a of the convex portion 21 is located at the central portion of the partition region 22. The inside of the convex portion 21 is filled with the constituent fibers 25 of the surface sheet 2. In the present invention, the recessed portion other than the linear portion is not excluded, but from the viewpoint of forming a good convex portion 21, the linear recessed portion is preferable.

In this way, the recessed portions 20 and the convex portions 21 are alternately arranged in the vertical direction X and the horizontal direction Y of the surface sheet 2, so that the contact area of the napkin 1 with the skin of the wearer is reduced. Effectively prevents stuffiness and rashes. Further, since the convex portion 21 (partition area 22) is surrounded by the recessed portion 20 and has a closed shape in a plan view, the convex portion 21 is not surrounded by the recessed portion 20 as compared with the case where the convex portion 21 is not surrounded by the recessed portion 20. Since the constituent fibers in the convex portion 21 are easily stretched in the thickness direction of the surface sheet 2, the thickness of the convex portion 21 is increased, whereby 1) the liquid permeates quickly and the liquid residue is small, and the surface sheet 2 The contact area with the skin is reduced, and 2) the convex portions 21 are formed in a regular pattern, so that the visual impression is improved.

As the surface sheet having a concavo-convex structure, instead of the one having the above-mentioned structure, a surface sheet having a concavo-convex structure having hollow convex portions, and ridges in which the convex portions and the concave portions extend in the vertical direction or the horizontal direction of the napkin 1, respectively. It may be a surface sheet or the like which is a groove portion. However, from the viewpoint of absorption of menstrual blood, the above-mentioned uneven surface sheet having a solid structure is preferable.

As the back sheet 3, various materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation, and a moisture-permeable resin film or a non-moisture-permeable resin film can be used. ..

The second sheet 5 is preferably made of a hydrophilic non-woven fabric or a hydrophilic fiber aggregate. Examples of the non-woven fabric include air-through non-woven fabric, point-bonded non-woven fabric, resin-bonded non-woven fabric, spunlace non-woven fabric, air raid non-woven fabric and the like.
The basis weight of the second sheet 5 is preferably 10 g / m ² or more and 50 g / m ² or less, and more preferably 15 g / m ² or more and 40 g / m ² or less. The thickness of the second sheet 5 is preferably 0.1 mm or more and 5 mm or less.

In the napkin 1, it is preferable that the front surface sheet 2 and the absorber 4 and the absorber 4 and the back surface sheet 3 are fixed by applying an adhesive. The adhesive can be applied by a known means, for example, a slot coat gun, a spiral spray gun, a spray gun, or a dot gun, and in the napkin 1, it can be applied in a spiral shape using a spiral spray gun. preferable. As the adhesive to be applied, for example, a hot melt adhesive is preferably used. The amount of the hot melt adhesive applied is preferably 1.5 g / m ² or more and 10 g / m ² or less.

The action effect and estimation mechanism of the above-mentioned napkin 1 will be described.
In the napkin 1, as shown in FIG. 4, the hemagglutination agent 8 is present on the non-skin facing surface side of the second sheet 5 in contact with the absorber 4. Therefore, during the use of the napkin 1, menstrual blood is separated into erythrocytes and plasma by the hemagglutination agent 8 contained in the second sheet 5 located on the skin-facing surface side of the absorber 4, and two or more erythrocytes are separated. Aggregates formed by agglutination are easily captured at the interface between the second sheet 5 and the absorber 4. Then, the separated plasma is absorbed by the highly absorbent polymer 41 of the absorber 4 located on the non-skin facing surface side of the second sheet 5. In the napkin 1, as shown in FIG. 4, the absorber 4 contains the synthetic fiber 46 and the cellulosic fiber 47, and has the fiber 461 having a portion in which the synthetic fiber 46 is oriented in the thickness direction Z. Therefore, even if the plasma as a liquid component is retained by the cellulosic fiber 47 and the highly absorbent polymer 41, the absorber 4 is not easily crushed by the body pressure during the use of the napkin 1, and the highly absorbent polymer that has absorbed the plasma. 41 is less likely to cause swelling inhibition, improved absorption efficiency, faster absorption rate of blood absorption and less likely to cause liquid return, and can absorb menstrual blood in spots, resulting in prevention of skin troubles. Can be done. Further, in the napkin 1 of the present embodiment, as shown in FIG. 4, the blood cell flocculant 8 contacts the non-skin facing surface side of the second sheet 5 in contact with the absorber 4 and the skin in contact with the second sheet 5 of the absorber 4. It exists on each facing surface side. Therefore, even if the hemagglutination agent 8 on the second sheet 5 does not separate the menstrual blood into erythrocytes and plasma, the hemagglutination agent 8 existing on the skin-facing surface side of the absorber 4 causes the menstrual blood to become erythrocytes and plasma. It is separated and can be absorbed more efficiently by the highly absorbent polymer 41.

Further, in the napkin 1, as shown in FIG. 4, the fiber 461 having a portion oriented in the thickness direction Z has a portion 461U exposed on the skin facing surface of the absorber 4 and the thickness of the absorber 4 is bisectoral. It is a fiber in which the portion 461D located on the non-skin facing surface side of the absorber 4 is connected by one to the bisector IL2 to be divided. Therefore, during the use of the napkin 1, the absorber 4 is less likely to be crushed by body pressure, the highly absorbent polymer 41 that has absorbed plasma is less likely to cause swelling inhibition, the absorption efficiency is further improved, and menstrual blood is spotted. It can be absorbed and skin troubles can be further prevented.

Further, in the napkin 1, as shown in FIG. 4, the absorber 4 made of the absorbent sheet has a relatively high absorbency with the polymer-rich region PT having a relatively large amount of the highly absorbent polymer 41 in cross section. It has a fiber-rich region FT with a small amount of polymer 41, and has a portion used by arranging the fiber-rich region FT on the skin-facing surface side. Therefore, in the portion where the fiber-rich region FT is arranged on the skin-facing surface side, the polymer-rich region PT is arranged on the non-skin-facing surface side, and the blood cell flocculant contained in the second sheet 5 is used. The menstrual blood plasma separated by No. 8 is mainly absorbed by the highly absorbent polymer 41 of the polymer-rich region PT in the lower layer, and the absorption rate of blood absorption tends to be increased, so that the menstrual blood is spotted. It will be able to absorb more.

Further, in the napkin 1, as shown in FIG. 4, the hemagglutination agent 8 is arranged in the fiber-rich region FT on the skin-facing surface side in contact with the second sheet 5 in the absorber 4. Therefore, the menstrual plasma separated by the hemagglutination agent 8 contained in the second sheet 5 and the hemagglutination agent 8 arranged in the fiber-rich region FT of the absorber 4 has a high polymer-rich region PT in the lower layer. The absorbable polymer 41 will be mainly absorbed, the absorption rate of absorbing blood will be further increased, and menstrual blood will be further absorbed in spots.

From the viewpoint of further exerting the above-mentioned effects, the contact angle between the fibers 51 constituting the second sheet 5 and the ion-exchanged water is preferably 70 degrees or more, and more preferably 75 degrees or more. The upper limit of the contact angle of the fibers 51 constituting the second sheet 5 is not particularly limited, but if it is 85 degrees or less, a sufficiently satisfactory effect can be obtained. The contact angle of the fibers 51 constituting the second sheet 5 is preferably larger than the contact angle between the synthetic fibers 46 and the cellulosic fibers 47 constituting the absorber 4 and the ion-exchanged water. The contact angle between the synthetic fiber 46 and the ion-exchanged water is preferably 75 degrees or less, and more preferably 70 degrees or less. Further, the contact angle between the cellulosic fiber 47 and the ion-exchanged water is preferably 50 degrees or less, and more preferably 40 degrees or less.
The contact angle between the fibers 51 constituting the second sheet 5, the synthetic fibers 46 or the cellulosic fibers 47 constituting the absorber 4, and the ion-exchanged water is measured by the following method. The contact angle measured by the following method means that the smaller the value, the higher the hydrophilicity.

[Measurement method of contact angle]
For the measurement of the contact angle, for example, a contact angle meter MCA-J manufactured by Kyowa Interface Science Co., Ltd. is used. Specifically, after dropping ion-exchanged water (about 20 picolitres) on the surface of the fiber 51 constituting the second sheet 5, the contact angle is immediately measured using the contact angle meter. The measurement is performed at five or more points of the fibers 51 constituting the second sheet 5, and the average value thereof is taken as the contact angle. The synthetic fiber 46 or the cellulosic fiber 47 constituting the absorber 4 is also measured in the same manner. The measurement environment temperature is 22 ° C.

Although the present invention has been described above based on the preferred embodiment thereof, the sanitary absorbent article of the present invention is not limited to the napkin 1 of the embodiment, and can be appropriately modified.
For example, in the napkin 1, as shown in FIGS. 3 and 4, the blood cell flocculant 8 contacts the non-skin facing surface NT in contact with the absorber 4 in the second sheet 5 and the skin in contact with the second sheet 5 in the absorber 4. Although present on each of the facing HTs, the blood cell flocculant 8 is a non-skin facing NT in contact with the absorber 4 in the second sheet 5 or a skin facing side in contact with the second sheet 5 in the absorber 4. It may be HT, and it is preferable that it exists on the non-skin facing surface side NT of the second sheet 5.

Further, as shown in FIGS. 3 and 4, the hemagglutination agent 8 is arranged on the absorber 4 formed of the absorbent sheet, but is not formed of the absorbent sheet. And may be arranged on an absorber formed of a core wrap sheet that wraps the absorbent core. When the hemagglutination agent 8 is arranged in the absorber formed of the absorbent core and the core wrap sheet, the absorbent core is formed of the highly absorbent polymer 41, the synthetic fiber 46, and the cellulosic fiber 47. At the same time, it is preferable that the hemagglutination agent 8 is arranged on a core wrap sheet formed of a tissue paper or the like that wraps the absorbent core.

Further, as shown in FIGS. 3 and 4, the hemagglutination agent 8 is arranged only on the main body absorbent sheet 401 forming a two-layer structure composed of the front surface side absorbent sheet 401a and the back surface side absorbent sheet 401b. However, the hemagglutination agent 8 is contained not only in the main body absorbent sheet 401 but also in the central absorbent sheet 402 forming a three-layer structure composed of the upper absorbent sheet 402a, the intermediate absorbent sheet 402c and the lower absorbent sheet 402b. It may be arranged. When the hemagglutination agent 8 is arranged in this way, the hemagglutination agent 8 is present in the polymer-rich region PT and the fiber-rich region FT, and is present in the fiber-rich region FT more than the polymer-rich region PT. Is preferable. Further, when the hemagglutination agent 8 is arranged in the absorber 4 having a multilayer structure in this way, the hemagglutination agent 8 contained is the same blood cells in any of the absorbent sheets 401a, 401b, 402a, 402b, 402c. It may be a flocculant 8 or a different hemagglutin 8.

Further, as shown in FIG. 4, the absorbent sheet constituting the absorber 4 is formed of two layers of the polymer-rich region PT and the fiber-rich region FT, but the polymer-rich region PT and the fiber-rich region FT are formed. It may not be formed, and may be formed in three or more layers having a polymer-rich region PT and a fiber-rich region FT.

Further, the napkin 1 is formed with a leak-proof groove (not shown) having a well-known technique, that is, a plane line-of-sight high-density portion (not shown) in which the surface sheet 2 and the absorber 4 are integrally recessed on the surface facing the skin. This is preferable from the viewpoint of suppressing lateral leakage of body fluid because it is difficult for excretory fluid such as menstrual blood to move to the outside of the leak-proof groove. As the shape of the leak-proof groove, the excretion portion facing portion B has a curved shape that is convex toward the outside in the lateral direction Y or a curved shape that is convex toward the inside of the lateral direction Y. The one is preferable.

Further, the sanitary absorbent article for menstrual blood absorption of the present invention may be a panty liner (pantyliner) or the like in addition to a sanitary napkin.

1 Sanitary napkin (sanitary absorbent article)
2 Front sheet 3 Back sheet 4 Absorber 401 Main body absorbent sheet 401a Front side absorbent sheet 401b Back side absorbent sheet 402 Central absorbent sheet 402a Upper absorbent sheet 402b Lower absorbent sheet 402c Intermediate absorbent sheet 41 High absorption Sex polymer 46 Synthetic fiber 461 Fiber including a portion oriented in the thickness direction 47 Cellulose fiber 5 Second sheet 51 Fibers constituting the second sheet 8 Blood cell flocculant FT Fiber rich region PT Polymer rich region

Claims (5)

Physiological use including an absorber containing a highly absorbent polymer, a front surface sheet and a back surface sheet sandwiching the absorber, and a second sheet composed of a non-woven fabric arranged between the front surface sheet and the absorber. It is an absorbent article
The sanitary absorbent article comprises a hemagglutinant and
The absorber contains synthetic fibers and cellulosic fibers,
In the cross-sectional view along the thickness direction of the absorber, the mass ratio of the highly absorbent polymer to the total amount of the mass of the synthetic fiber and the fiber containing the cellulosic fiber and the mass of the highly absorbent polymer is relative. It has a polymer-rich region that is relatively high and a fiber-rich region whose mass ratio is relatively lower than that of the polymer-rich region.
The absorber is provided with a portion used by arranging the fiber-rich region on the skin-facing surface side, and in the portion, the polymer-rich region is arranged on the non-skin-facing surface side of the absorber.
The synthetic fiber has a fiber including a portion oriented in the thickness direction inside the absorber.
The fiber including the portion oriented in the thickness direction includes a fiber in which a portion located in the fiber-rich region and a portion located in the polymer-rich region are connected by one.
The hemagglutinant is the skin-facing surface side of the second sheet that contacts the surface sheet, the non-skin-facing surface side of the second sheet that contacts the absorber , and the skin that contacts the second sheet of the absorber. A sanitary absorbent article that exists in the fiber-rich region on the facing surface side and is more present on the non-skin facing surface side than on the skin facing surface side in the second sheet . The sanitary absorbent article according to claim 1, wherein the ratio of the synthetic fiber to the absorber is 30% by mass or more and 80% by mass or less. The fiber including the portion oriented in the thickness direction is such that the portion exposed on the skin-facing surface of the absorber and the non-skin-facing portion of the absorber rather than the bisector that bisects the thickness of the absorber. The sanitary absorbent article according to claim 1 or 2, which is a fiber in which a portion located on the surface side is connected by a single fiber. The blood coagulant may be a sanitary absorbent article according to any one of claims 1 to 3 is a cationic polymer. The contact angle between the fibers constituting the second sheet and the ion-exchanged water is 70 degrees or more, and the contact angle of the second sheet is the ion-exchanged water with each of the synthetic fibers and the cellulosic fibers constituting the absorber. The sanitary absorbent article according to any one of claims 1 to 4 , which is larger than the contact angle with.

Images